A Review of Research on CRISPR/Cas9 Gene Editing Technology in Disease Treatment
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index; 16 of the 28 sources its claims cite were checked for support.
Abstract
The appearance of CRISPR/Cas9 gene editing technology marks a revolutionary advance in the field of gene editing. With its high degree of specificity and efficiency, this technology enables precise modification of genome-specific loci. This paper reviews the mechanism of CRISPR/Cas9 and its applications in various fields such as genetic disease treatment, cancer therapy, antiviral therapy, gene function research and virus detection. Also, the challenges of off-target effects are discussed and strategies to minimize them are proposed, The purpose of this study is to propose applications and innovations of CRISPR/Cas9 technology in medical therapeutics while addressing its current limitations.
Overview
CoChat Summary
TL;DR
This review describes the CRISPR/Cas9 mechanism and its applications in hereditary disease, cancer, antiviral therapy, gene function research, and virus detection, while outlining challenges such as off-target effects. It concludes that CRISPR/Cas9 is a flexible genome-editing tool with therapeutic promise, but clinical translation requires improved specificity, delivery, safety, and ethical/regulatory oversight.
Key findings
- The review outlines the CRISPR/Cas9 mechanism: sgRNA guides Cas9 to target DNA; Cas9 cuts 3 bp upstream of the PAM, producing a blunt double-strand break; repair occurs via NHEJ (indels) or HDR (precise editing). CRISPR arrays contain repeat sequences of 25–35 bp separated by spacer sequences of 30–40 bp.
- Applications discussed include hereditary diseases (sickle cell anemia, β-thalassemia, DMD, familial hypercholesterolemia via PCSK9), cancer immunotherapy (PD-1 knockout), antiviral therapy (HIV-1 LTR targeting), gene function studies (p53 knockout mice), and virus detection (SHERLOCK for SARS-CoV-2 and dengue).
- Cited examples: Tabebordbar used AAV-delivered CRISPR/Cas9 in an mdx mouse model to delete mutated exon 23, restoring the Dmd reading frame; Rupp et al. found PD-1 knockout T cells had stronger anti-tumor effects and significantly prolonged mouse survival; Ebina’s group reduced HIV-1 LTR-driven expression and removed latent HIV-1 provirus; p53 knockout mice showed high spontaneous tumorigenesis including lymphomas and osteosarcomas.
- The paper identifies off-target effects, delivery, immune response, genetic stability, and ethical issues as main challenges, and proposes optimizing sgRNA design, Cas9 variants, and safer delivery systems.
Methods
- Design: narrative review of CRISPR/Cas9 gene editing technology and its disease-treatment applications.
- Data/sample: no primary experimental sample or dataset; the paper synthesizes published studies and cited examples across genetic disease, cancer, antiviral, gene function, and virus detection.
- Main analysis: descriptive synthesis of mechanism and applications; no systematic search strategy, inclusion criteria, or quantitative/meta-analytic analysis is described.
Limitations
- The paper states challenges including off-target effects, delivery issues, immune response, genetic stability, and ethical controversies, especially in embryos and germ cells.
- The paper states that off-target effects remain an important concern despite sgRNA design and Cas9 variant improvements, and that long-term safety assessments and ethical/regulatory frameworks are needed.
- Evident from the text: as a review, it lacks a described systematic search or quantitative synthesis; citation numbering in the text appears inconsistent with the reference list (e.g., Tabebordbar, PCSK9, p53, and SHERLOCK citations), limiting verifiability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
3 Valid · 13 Not valid · 12 Not checked · 4 Own results and interpretations
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Joung, J.'s team employed the SHERLOCK technique to detect SARS-CoV-2 viral RNA using the CRISPR-Cas13a system.”
§ A Review of Research on CRISPR/Cas9 Gene Editing Technology in Disease Treatment > 3.5. Virus detection
What the sources say
- Could not verifycites [17] 17. Wang, T., Birsoy, K., Hughes, N. W., Krupczak, K. M., Post, Y., Wei, J. J., Lander, E. S., & Sabatini, D. M. (2015). Identification and characterization of essential genes in the human genome. Science (New York, N.Y.), 350(6264), 1096- 1101. https://doi.org/10.1126/science.aac7041 sourceExperimental — accuracy not yet measured
The paper’s Abstract describes CRISPR-Cas9 and gene-trap screens for essential genes in human cells. Searches for Joung, SHERLOCK, SARS-CoV-2, Cas13a, and viral RNA detection found no passage addressing the claimed diagnostic technique. (LLM, conf=0.78)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“This suggests that targeting and disrupting PCSK9 with CRISPR/Cas9 technology could offer a treatment for familial hypercholesterolemia [14].”
§ A Review of Research on CRISPR/Cas9 Gene Editing Technology in Disease Treatment > 3.1. Treatment of hereditary diseases
What the sources say
- Could not verifycites [14] 14. Joung, J., Ladha, A., Saito, M., Segel, M., Bruneau, R., Huang, M. W., Kim, N. G., Yu, X., Li, J., Walker, B. D., Greninger, A. L., Jerome, K. R., Gootenberg, J. S., Abudayyeh, O. O., & Zhang, F. (2020). Point-of-care testing for COVID-19 using SHERLOCK diagnostics. medRxiv : the preprint server for health sciences, 2020.05.04.20091231. https://doi.org/10.1101/2020.05.04.20091231 sourceExperimental — accuracy not yet measured
The Introduction and Materials and Methods describe a CRISPR-Cas12b test targeting the SARS-CoV-2 N gene, not a treatment. Searches for PCSK9, familial hypercholesterolemia, and cholesterol-related genome editing found no passage addressing the claimed CRISPR/Cas9 treatment. (LLM, conf=0.75)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“The team led by Dennis M. K. found that the preprotein convertase subtilisin/kexin type 9 (PCSK9) is a gene participated in cholesterol metabolism.”
§ A Review of Research on CRISPR/Cas9 Gene Editing Technology in Disease Treatment > 3.1. Treatment of hereditary diseases
What the sources say
- Could not verifycites [14] 14. Joung, J., Ladha, A., Saito, M., Segel, M., Bruneau, R., Huang, M. W., Kim, N. G., Yu, X., Li, J., Walker, B. D., Greninger, A. L., Jerome, K. R., Gootenberg, J. S., Abudayyeh, O. O., & Zhang, F. (2020). Point-of-care testing for COVID-19 using SHERLOCK diagnostics. medRxiv : the preprint server for health sciences, 2020.05.04.20091231. https://doi.org/10.1101/2020.05.04.20091231 sourceExperimental — accuracy not yet measured
The Results and Materials and Methods sections discuss a SARS-CoV-2 diagnostic assay and its target, the viral N gene. Searches for PCSK9, cholesterol metabolism, and Dennis M. K. found no passage in our copy addressing the attributed finding; page numbers were not available. (LLM, conf=0.78)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Donehower, L.A. and his team found that mice with the P53 gene knocked out exhibit a high frequency of spontaneous tumorigenesis, including lymphomas, osteosarcomas, and other types of tumors.”
§ A Review of Research on CRISPR/Cas9 Gene Editing Technology in Disease Treatment > 3.4. Gene Function Studies
What the sources say
- Could not verifycites [16] 16. Rupp, L. J., Schumann, K., Roybal, K. T., Gate, R. E., Ye, C. J., Lim, W. A., & Marson, A. (2017). CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells. Scientific reports, 7(1), 737. https://doi.org/10.1038/s41598-017-00462-8 sourceExperimental — accuracy not yet measured
The Materials and Methods section (page not provided) describes mice implanted with K562 tumor cells, and the Discussion concerns disruption of Pdcd1 in CAR T cells. Searches for Donehower, p53, spontaneous tumors, lymphoma, and osteosarcoma found no passage addressing the claimed p53-knockout finding. (LLM, conf=0.78)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“In addition, the system was able to remove internal viral genes from host cell chromosomes.”
§ A Review of Research on CRISPR/Cas9 Gene Editing Technology in Disease Treatment > 3.3. Antiviral therapy
What the sources say
- Could not verifycites [12] 12. ROTHGANGL T,DENNIS M K,LIN P J C,et al.In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels[J].Nat Biotechnol,2021,39(8):949-957. sourceExperimental — accuracy not yet measured
The Main section describes CRISPR–Cas genome editing and adenine base editing, but does not address removal of viral genes from host chromosomes. Searches for the claim’s wording and for excision of integrated viral DNA found no passage reporting that result (page not provided). (LLM, conf=0.76)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
12 more claims · 4 with their cited sources checked
Create a free account to see all 32 claims and every source verdict.
- It may state two separate claims as one. 13
- Probably not a substantial claim. 3
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ A Review of Research on CRISPR/Cas9 Gene Editing Technology in Disease Treatment > 3.4. Gene Function Studies
“Donehower, L.A. and his team found that mice with the P53 gene knocked out exhibit a high frequency of spontaneous tumorigenesis, including lymphomas, osteosarcomas, and other types of tumors.This observation suggests that p53 plays a crucial role in tumor suppression.Mouse cells lacking p53 are unable to effectively arrest cell cycle progression after DNA damage, leading to genomic instability [16].”
§ A Review of Research on CRISPR/Cas9 Gene Editing Technology in Disease Treatment > References
“16. Rupp, L. J., Schumann, K., Roybal, K. T., Gate, R. E., Ye, C. J., Lim, W. A., & Marson, A. (2017). CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ A Review of Research on CRISPR/Cas9 Gene Editing Technology in Disease Treatment > 3.5. Virus detection
“This assay is highly sensitive and specific, capable of detecting low concentrations of SARS-CoV-2 RNA in a short period of time [17].”
§ A Review of Research on CRISPR/Cas9 Gene Editing Technology in Disease Treatment > References
“17. Wang, T., Birsoy, K., Hughes, N. W., Krupczak, K. M., Post, Y., Wei, J. J., Lander, E. S., & Sabatini, D. M. (2015). Identification and characterization of essential genes in the human genome.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ A Review of Research on CRISPR/Cas9 Gene Editing Technology in Disease Treatment > 3.1. Treatment of hereditary diseases
“For instance, Tabebordbar [13] used adeno-associated viral vectors to deliver CRISPR/Cas9 into an mdx mouse model, deleting the mutated exon 23.”
§ A Review of Research on CRISPR/Cas9 Gene Editing Technology in Disease Treatment > References
“13. Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Jr, Butel, J. S., & Bradley, A. (1992). Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ A Review of Research on CRISPR/Cas9 Gene Editing Technology in Disease Treatment > 3.3. Antiviral therapy
“The CRISPR/Cas9 components were delivered into T cells expressing the HIV-1 LTR, both in silenced and inducible states, to examine their effect on expression driven by the LTR.[11].”
§ A Review of Research on CRISPR/Cas9 Gene Editing Technology in Disease Treatment > References
“11. Tabebordbar M, Zhu K, Cheng JK, et al. In vivo gene editing in dystrophic mouse muscle and muscle stem cells [J] . Science, 2016, 351(6271): 407-411.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ A Review of Research on CRISPR/Cas9 Gene Editing Technology in Disease Treatment > 3.3. Antiviral therapy
“The results demonstrated that CRISPR/Cas9 can indeed block HIV-1 transcription and directly remove latent HIV-1 proviruses from the host genome [12].”
§ A Review of Research on CRISPR/Cas9 Gene Editing Technology in Disease Treatment > References
“12. ROTHGANGL T,DENNIS M K,LIN P J C,et al.In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels[J].Nat Biotechnol,2021,39(8):949-957.”
1 more finding
Create a free account to see every finding of this check.
Citations
Cites
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649 · cited 1×
“For instance, Tabebordbar [13] used adeno-associated viral vectors to deliver CRISPR/Cas9 into an mdx mouse model, deleting the mutated exon 23.”
Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9
Doench, J. G., Fusi, N., Sullender, M., Hegde, M., Vaimberg, E. W., Donovan, K. F., Smith, I., Tothova, Z., Wilen, C., Orchard, R., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3437 · Cited by 4,637 · cited 1×
“Additionally, it can identify genes related to drug resistance in cancer cells and facilitate research on overcoming this resistance [8].”
Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a, and Csm6
Gootenberg, J. S., Abudayyeh, O. O., Kellner, M. J., Joung, J., Collins, J. J., & Zhang, F. (2018) · Science · doi:10.1126/science.aaq0179 · Cited by 2,638
Identification and characterization of essential genes in the human genome
Wang, T., Birsoy, K., Hughes, N. W., Krupczak, K. M., Post, Y., Wei, J. J., Lander, E. S., & Sabatini, D. M. (2015) · Science · doi:10.1126/science.aac7041 · Cited by 1,617
In vivo gene editing in dystrophic mouse muscle and muscle stem cells
Tabebordbar, M., Zhu, K., Cheng, J. K. W., Chew, W. L., Widrick, J. J., Yan, W. X., Maesner, C., Wu, E. Y., Xiao, R., Ran, F. A., et al. (2016) · Science · doi:10.1126/science.aad5177 · Cited by 1,046 · cited 1×
“[11].”
Rupp, L. J., Schumann, K., Roybal, K. T., Gate, R. E., Ye, C. J., Lim, W. A., & Marson, A. (2017) · Scientific Reports · doi:10.1038/s41598-017-00462-8 · Cited by 757 · cited 1×
“Mouse cells lacking p53 are unable to effectively arrest cell cycle progression after DNA damage, leading to genomic instability [16].”
Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus
Ebina, H., Misawa, N., Kanemura, Y., & Koyanagi, Y. (2013) · Scientific Reports · doi:10.1038/srep02510 · Cited by 565 · cited 1×
“Off-target effects refer to the possibility that the CRISPR/Cas9 system may cut DNA at a non-specific location other than the target DNA, resulting in unwanted gene mutations or interference with normal gene function[10].”
Current applications and future perspective of CRISPR/Cas9 gene editing in cancer
Wang, S.-W., Gao, C., Zheng, Y.-M., Yi, L., Lu, J.-C., Huang, X.-Y., Cai, J.-B., Zhang, P.-F., Cui, Y.-H., & Ke, A.-W. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01518-8 · Cited by 478 · cited 1×
“For viral infections, CRISPR/Cas9 can be used to cut viral genomes and inhibit viral replication, such as in the case of HIV and Hepatitis B[7].”
In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels
Rothgangl, T., Dennis, M. K., Lin, P. J. C., Oka, R., Witzigmann, D., Villiger, L., Qi, W., Hruzova, M., Kissling, L., Lenggenhager, D., et al. (2021) · Nature Biotechnology · doi:10.1038/s41587-021-00933-4 · Cited by 378
Point-of-care testing for COVID-19 using SHERLOCK diagnostics
Joung, J., Ladha, A., Saito, M., Segel, M., Bruneau, R., Huang, M.-L. W., Kim, N.-G., Yu, X., Li, J., Walker, B. D., et al. (2020) · doi:10.1101/2020.05.04.20091231 · Cited by 317 · cited 1×
“This suggests that targeting and disrupting PCSK9 with CRISPR/Cas9 technology could offer a treatment for familial hypercholesterolemia [14].”
CRISPR-Cas9 for cancer therapy: Opportunities and challenges
Chen, M., Mao, A., Xu, M., Weng, Q., Mao, J., & Ji, J. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.01.017 · Cited by 272
Advances in therapeutic CRISPR/Cas9 genome editing
Savić, N., & Schwank, G. (2016) · Translational Research · doi:10.1016/j.trsl.2015.09.008 · Cited by 257 · cited 1×
“[6] CRISPR/Cas9 technology allows for screening cancer cells to determine their gene specificity.”
Application of CRISPR/Cas9-Based Gene Editing in HIV-1/AIDS Therapy
Xiao, Q., Guo, D., & Chen, S. (2019) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2019.00069 · Cited by 179
Research works printed but not linked: 2
- [2]2. Wang, L., & Zhao, T. (2017). The principle of CRISPR/Cas9 and its research progress in disease treatment. *Developmental Medicine Electronic Journal*, (1), 35-44.
- [3]3. Huang, J., & Fang, S. (2024). Advances in molecular diagnostics applications based on the CRISPR-Cas system. *Journal of Molecular Diagnostics and Therapy*, (6), 989- 992+1001. https://doi.org/10.19930/j.cnki.jmdt.2024.06.004 · doi:10.19930/j.cnki.jmdt.2024.06.004
Cited by
Balatsky, V., Саєнко, А. М., & Peka, M. (2026) · BMC Genomics · doi:10.1186/s12864-026-12904-7 · Cited by 2
“One of the approaches to identifying and confirming gene causality involves gene knockout or targeted gene modification using genome editing tools such as CRISPR-Cas9 technology [268, 269].”
Metadata
- Authors
- Jing, X.
- Affiliations
- Beijing University of Chemical Technology (CN)
- Corresponding author
- Jing, Xiao
- Venue
- Academic Journal of Science and Technology
- Publisher
- Darcy & Roy Press Co. Ltd.
- Published
- 2024-12-26
- Volume
- 13
- Issue
- 3
- Pages
- 132-134
- ISSN
- 2771-3032 (ISSN-L)
- OpenAlex
- W4405808461
- Semantic Scholar
- ab4d5955c45c6d4afeffe674694cb40755fbdc02
- Cited by
- 0
- References
- 11
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Locations
- Academic Journal of Science and Technology (publishedVersion, cc-by)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA regulation and disease
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- CRISPR/Cas9, genome editing, genetic disease treatment, cancer therapy, antiviral therapy, virus detection, off-target effects
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.